1.Date of the board of directors submitted or approved:2023/08/07
2.Date of the audit committee approved:2023/08/07
3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2023/01/01~2023/06/30
4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):11,654
5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):(37,828)
6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):(985,053)
7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):(85,532)
8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):(86,534)
9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):45,725
10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):0.20
11.Total assets end of the period (thousand NTD):6,407,501
12.Total liabilities end of the period (thousand NTD):330,191
13.Equity attributable to owners of parent end of the period (thousand NTD):4,870,322
14.Any other matters that need to be specified:
The number of directors assigned by the Company decrease from 7 to 2 due to AP Biosciences’ re-election of directors in advance on 2023/5/23 to
coordinate with its application for the trading of emerging stocks and the plan of listing. Given the voting shares held by other shareholders, the
fact that the number of directors the Company assigned is less than 50%, and the fact that the Company has no control over AP Biosciences’ relevant
activities, the Company is considered to lose control of AP Biosciences. The Company derecognized the assets, liabilities, and non-controlling
interests of the former subsidiary, remeasured the fair value of the shareholding of AP Biosciences, and recognized the difference as a one-time
gain on disposal of NT$ 851,687 thousand (non-operating income) in accordance with IFRSs on the date it loses control of AP Biosciences.